Eli Lilly LLY-1.94%decrease; red down pointing triangle reported higher fourth-quarter profit on the back of surging demand for its GLP-1 weight-loss drugs. The pharmaceutical company reported net ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing company Seamless Therapeutics. This morning’s deal with Seamless centers on ...

Eli Lilly & Co. struck a deal worth more than $1.1 billion with German biotech Seamless Therapeutics GmbH to develop gene therapies for hearing loss. Closely-held Seamless will design a type of enzyme ...

Eli Lilly is at the forefront of the GLP-1 weight loss drug market. The company's leading position is already being tested by Novo Nordisk's GLP-1 weight loss pill. Merck and Bristol Myers Squibb have ...

Evangeline Lilly is opening up about her costly treatment following a traumatic brain injury. “I have spent a lot of money getting evaluated and getting targeted, expert advice on how to heal my brain ...

Drug giant Eli Lilly LLY3.66%increase; green up pointing triangle said it plans to open a $3.5 billion plant in Pennsylvania’s Lehigh Valley, giving the region an economic shot in the arm and helping ...

Jan 28 (Reuters) - U.S. drugmaker Eli Lilly (LLY.N), opens new tab signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based startup said on Wednesday, to develop and ...

Top executives from drugmakers big and small told CNBC that the next phase of the obesity drug market will be defined by a broader range of treatment options and improved access for patients. CNBC ...

Jan 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025, more than double what ...

Altimmune (ALT) surged 35.4% after FDA granted Breakthrough Therapy Designation for pemvidutide on January 16. Altimmune beat earnings estimates in all four quarters and narrowed annual losses 45% to ...

WASHINGTON (Reuters) — Eli Lilly announced on Friday that it will build a pharmaceutical manufacturing facility in Pennsylvania, its fourth new site in an effort to expand U.S. production and bolster ...

In its latest earnings report, Eli Lilly and Company (NYSE: LLY) once again showed why it has become by far one of the world’s most valuable healthcare stocks. Year-to-date, Eli Lilly’s market ...